lobbying_activities: 1912445

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1912445	d80eef78-b052-4f2f-8077-6a7b069e5f45	Q4	ACADEMY OF MANAGED CARE PHARMACY	48793	ACADEMY OF MANAGED CARE PHARMACY	2016	fourth_quarter	PHA	Medicare Part D issues concerning managed care pharmacy, comments to FDA on BsUFA II reauthorization citing a need for biosimilars education and post market surveillance, comments in support of 21st Century Cures Act to support Section 3037 - Health care economic information, comments to CMS regarding implementation of CARA - P.L. 114-198, and comments to CMS on Medicare Part D MTM program. Meetings with Congressional office staff to seek support for amending current law consistent with HIPAA to allow health plans to access patient addiction records. Meeting with OMB to discuss impact of the SAMSHA pending final rule on confidentiality of substance abuse records (42 CFR Part 2).	Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)		158000	0	0	2017-01-13T11:16:14-05:00